Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.61 |
| ▸ | JUN | P05412 | 1/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979554 | 0.86 | CYP2A6 (0.61) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL10370773 | 0.85 | CYP2A6 (0.66) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL1233284 | 0.84 | CYP2A6 (0.63) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL8905373 | 0.83 | CYP2A6 (0.58) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL30138881 | 0.83 | CYP2A6 (0.58) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL12174999 | 0.82 | CYP2A6 (0.61) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL6710511 | 0.82 | CYP2A6 (0.61) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL13995272 | 0.81 | CYP2A6 (0.56) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL8869956 | 0.81 | CYP2A6 (0.56) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 | |
| SCHEMBL6673016 | 0.81 | CYP2A6 (0.59) | CYP2A6JUNMAPK8MAPK9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| US-8202894-B2 | Microbiocides | SYNGENTA CROP PROTECTION LLC (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100227898-A1 | NOVEL MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| EP-2170858-A2 | NOVEL MICROBIOCIDES | Syngeta Participations AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009003672-A2 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-6713505-B2 | SUCH AS N-(2-((3-(AMINOOXOACETYL)-2-ETHYLBENZO(B)THIOPHEN-4-YL)OXY) ACETYL)GLYCINE; SECRETORY PHOSPHOLIPASE A2 (SPLA2) | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20030236232-A1 | Novel spla2 inhibitors | ELI LILLY AND COMPANY | 2003-12-25 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| EP-1224932-A1 | DRUGS INHIBITING CELL DEATH | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| EP-0422119-A4 | BENZOTHIOPHENE DERIVATIVES USEFUL FOR MODIFYING FEEDING BEHAVIOR AND OBSESSIVE-COMPULSIVE BEHAVIOR | — | 1991-11-13 | — | — | EP | disclosed |
| EP-0422119-A1 | BENZOTHIOPHENE DERIVATIVES USEFUL FOR MODIFYING FEEDING BEHAVIOR AND OBSESSIVE-COMPULSIVE BEHAVIOR | NEUREX CORPORATION (US) | 1991-04-17 | — | — | EP | disclosed |
| WO-1989012447-A1 | BENZOTHIOPHENE DERIVATIVES USEFUL FOR MODIFYING FEEDING BEHAVIOR AND OBSESSIVE-COMPULSIVE BEHAVIOR | NEUREX CORPORATION (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236232-A1 | Novel spla2 inhibitors | PLA2G2E, PLA2G4B, PLA2G12A | CYP2A6 1690/4885JUN 2200/4885MAPK8 4172/4885 |
| US-20100227898-A1 | NOVEL MICROBIOCIDES | FPR1, CD14, MSR1 | CYP2A6 747/4885JUN 3299/4885MAPK8 4234/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | CYP2A6 522/4885JUN 3918/4885MAPK8 4269/4885 |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | CYP2A6 152/4885JUN 824/4885MAPK8 2531/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CYP2A6 279/4885JUN 936/4885MAPK8 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.